HI
VKTX icon

Horizon Investments’s Viking Therapeutics VKTX Stock Holding History

Horizon Investments’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$429 Sell
11
-39
-78% -$1.26K ﹤0.01% 1357
2026
Q1 		$1.63K Buy
50
+39
+355% +$1.25K ﹤0.01% 1286
2025
Q4 		$387 Hold
11
– – ﹤0.01% 1274
2025
Q3 		$289 Buy
+11
New +$328 ﹤0.01% 1162

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Horizon Investments's VKTX Position: Q2 2026 in Review

Horizon Investments reduced its Viking Therapeutics (VKTX) stake by 78% in Q2 2026, selling an estimated $1.26K and leaving 11 shares worth $429. The position accounts for ﹤0.01% of the portfolio, ranked #1357.

Horizon Investments first reported a position in VKTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.63K in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Horizon Investments held 11 shares of Viking Therapeutics worth $429 as of Q2 2026.
  • Horizon Investments sold 39 Viking Therapeutics shares in Q2 2026, an estimated $1.26K.
  • Viking Therapeutics made up ﹤0.01% of Horizon Investments's portfolio in Q2 2026, its #1357 holding.
  • Horizon Investments first reported a position in Viking Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Horizon Investments's Viking Therapeutics position peaked at $1.63K in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Horizon Investments's 13F filing for Q2 2026, filed 13 Aug 2026.